329 related articles for article (PubMed ID: 23041061)
1. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
Puhr M; Hoefer J; Schäfer G; Erb HH; Oh SJ; Klocker H; Heidegger I; Neuwirt H; Culig Z
Am J Pathol; 2012 Dec; 181(6):2188-201. PubMed ID: 23041061
[TBL] [Abstract][Full Text] [Related]
2. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells.
Nalls D; Tang SN; Rodova M; Srivastava RK; Shankar S
PLoS One; 2011; 6(8):e24099. PubMed ID: 21909380
[TBL] [Abstract][Full Text] [Related]
3. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.
Hanrahan K; O'Neill A; Prencipe M; Bugler J; Murphy L; Fabre A; Puhr M; Culig Z; Murphy K; Watson RW
Mol Oncol; 2017 Mar; 11(3):251-265. PubMed ID: 28133913
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
5. Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma.
Cui SY; Huang JY; Chen YT; Song HZ; Feng B; Huang GC; Wang R; Chen LB; De W
Mol Cancer Res; 2013 Jul; 11(7):699-713. PubMed ID: 23562878
[TBL] [Abstract][Full Text] [Related]
6. Zerumbone inhibits epithelial-mesenchymal transition and cancer stem cells properties by inhibiting the β-catenin pathway through miR-200c.
Dermani FK; Amini R; Saidijam M; Pourjafar M; Saki S; Najafi R
J Cell Physiol; 2018 Dec; 233(12):9538-9547. PubMed ID: 29943808
[TBL] [Abstract][Full Text] [Related]
7. Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells.
Ren D; Wang M; Guo W; Huang S; Wang Z; Zhao X; Du H; Song L; Peng X
Cell Tissue Res; 2014 Dec; 358(3):763-78. PubMed ID: 25296715
[TBL] [Abstract][Full Text] [Related]
8. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205.
Massoner P; Thomm T; Mack B; Untergasser G; Martowicz A; Bobowski K; Klocker H; Gires O; Puhr M
Br J Cancer; 2014 Aug; 111(5):955-64. PubMed ID: 24992580
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway.
Pan Y; Chen J; Tao L; Zhang K; Wang R; Chu X; Chen L
Oncotarget; 2017 May; 8(20):33144-33158. PubMed ID: 28388536
[TBL] [Abstract][Full Text] [Related]
10. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
11. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells.
Han M; Liu M; Wang Y; Mo Z; Bi X; Liu Z; Fan Y; Chen X; Wu C
Mol Cell Biochem; 2012 Apr; 363(1-2):427-36. PubMed ID: 22187223
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-498 promotes proliferation, migration, and invasion of prostate cancer cells and decreases radiation sensitivity by targeting PTEN.
Duan XM; Liu XN; Li YX; Cao YQ; Silayiding A; Zhang RK; Wang JP
Kaohsiung J Med Sci; 2019 Nov; 35(11):659-671. PubMed ID: 31332950
[TBL] [Abstract][Full Text] [Related]
13. Effects of miR-200c on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism.
Shi R; Xiao H; Yang T; Chang L; Tian Y; Wu B; Xu H
Front Med; 2014 Dec; 8(4):456-63. PubMed ID: 25363395
[TBL] [Abstract][Full Text] [Related]
14. MiR-181a promotes epithelial to mesenchymal transition of prostate cancer cells by targeting TGIF2.
Zhiping C; Shijun T; Linhui W; Yapei W; Lianxi Q; Qiang D
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4835-4843. PubMed ID: 29164579
[TBL] [Abstract][Full Text] [Related]
15. Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial-Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1
Qian J; Shen S; Chen W; Chen N
Biomed Res Int; 2018; 2018():4174232. PubMed ID: 29568752
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-200c overexpression plays an inhibitory role in human pancreatic cancer stem cells by regulating epithelial-mesenchymal transition.
Ma C; Ding YC; Yu W; Wang Q; Meng B; Huang T
Minerva Med; 2015 Aug; 106(4):193-202. PubMed ID: 26081037
[TBL] [Abstract][Full Text] [Related]
17. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
18. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis.
Hur K; Toiyama Y; Takahashi M; Balaguer F; Nagasaka T; Koike J; Hemmi H; Koi M; Boland CR; Goel A
Gut; 2013 Sep; 62(9):1315-26. PubMed ID: 22735571
[TBL] [Abstract][Full Text] [Related]
20. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
